Stabile Marzia, Samarelli Rossella, Trerotoli Paolo, Fracassi Laura, Lacitignola Luca, Crovace Antonio, Staffieri Francesco
Department of Emergency and Organ Transplantation, PhD in Tissues and Organs Transplantation and Cellular Therapies, University of Bari, 70010 Bari, Italy.
Department of Emergency and Organ Transplantation, Section of Veterinary Clinics and Animal Production, University of Bari, 70010 Bari, Italy.
Vet Sci. 2019 Sep 4;6(3):72. doi: 10.3390/vetsci6030072.
Osteoarthritis (OA) is a chronic disease that requires a multimodal therapeutic approach. The aim of this study was to evaluate the effects of undenatured type II collagen (UC-II) as compared to robenacoxib in dogs affected by OA. Our hypothesis was that the two compounds would be similar (non-inferiority) in improving mobility. To test this hypothesis, a complete orthopedic examination, x-ray and the Liverpool Osteoarthritis in Dogs (LOAD) survey were performed in dogs affected by OA before and after the treatments. The study was designed as a clinical, randomized, controlled and prospective study. Sixty client-owned dogs were randomized in the R group ( = 30, robenacoxib 1 mg/kg/day for 30 days) and in the UC-II group ( = 30, UC-II 1 tablet/day for 30 days). Thirty days after the beginning of the treatment (T30), the dogs were reassessed for the LOAD, MOBILITY and CLINICAL scores. Based on the data obtained from the study, a significant reduction in LOAD and MOBILITY scores was recorded between T0 and T30 with a similar magnitude among the two groups (R = 31.5%, < 0.001; UC-II = 32.7%, = 0.013). The results of this study showed that UC-II and robenacoxib were able to similarly improve mobility of dogs affected by OA.
骨关节炎（OA）是一种需要多模式治疗方法的慢性疾病。本研究的目的是评估与罗贝考昔相比，未变性II型胶原蛋白（UC-II）对患骨关节炎犬的影响。我们的假设是这两种化合物在改善活动能力方面相似（非劣效性）。为了验证这一假设，在治疗前后对患骨关节炎的犬进行了全面的骨科检查、X光检查以及利物浦犬骨关节炎（LOAD）调查。该研究设计为一项临床、随机、对照和前瞻性研究。60只客户拥有的犬被随机分为R组（n = 30，罗贝考昔1 mg/kg/天，共30天）和UC-II组（n = 30，UC-II 1片/天，共30天）。治疗开始30天后（T30），对犬的LOAD、活动能力和临床评分进行重新评估。根据研究获得的数据，在T0和T30之间记录到LOAD和活动能力评分显著降低，两组降低幅度相似（R组 = 31.5%，P < 0.001；UC-II组 = 32.7%，P = 0.013）。本研究结果表明，UC-II和罗贝考昔能够同样地改善患骨关节炎犬的活动能力。
